Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?

Abstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissu...

Full description

Bibliographic Details
Main Authors: Santiago Roura, Carolina Gálvez-Montón, Clémentine Mirabel, Joaquim Vives, Antoni Bayes-Genis
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13287-017-0695-y
id doaj-158d248adc154b25b17c05aa0ccb5e86
record_format Article
spelling doaj-158d248adc154b25b17c05aa0ccb5e862020-11-25T00:43:16ZengBMCStem Cell Research & Therapy1757-65122017-10-018111110.1186/s13287-017-0695-yMesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?Santiago Roura0Carolina Gálvez-Montón1Clémentine Mirabel2Joaquim Vives3Antoni Bayes-Genis4ICREC Research Program, Germans Trias i Pujol Health Research InstituteICREC Research Program, Germans Trias i Pujol Health Research InstituteServei de Teràpia Cel∙lular, Banc de Sang i TeixitsServei de Teràpia Cel∙lular, Banc de Sang i TeixitsICREC Research Program, Germans Trias i Pujol Health Research InstituteAbstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.http://link.springer.com/article/10.1186/s13287-017-0695-yCardiac adipose tissueCardiac repairCell therapyGood manufacturing practiceMesenchymal stem cellsTissue engineering
collection DOAJ
language English
format Article
sources DOAJ
author Santiago Roura
Carolina Gálvez-Montón
Clémentine Mirabel
Joaquim Vives
Antoni Bayes-Genis
spellingShingle Santiago Roura
Carolina Gálvez-Montón
Clémentine Mirabel
Joaquim Vives
Antoni Bayes-Genis
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
Stem Cell Research & Therapy
Cardiac adipose tissue
Cardiac repair
Cell therapy
Good manufacturing practice
Mesenchymal stem cells
Tissue engineering
author_facet Santiago Roura
Carolina Gálvez-Montón
Clémentine Mirabel
Joaquim Vives
Antoni Bayes-Genis
author_sort Santiago Roura
title Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
title_short Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
title_full Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
title_fullStr Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
title_full_unstemmed Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
title_sort mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
publisher BMC
series Stem Cell Research & Therapy
issn 1757-6512
publishDate 2017-10-01
description Abstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
topic Cardiac adipose tissue
Cardiac repair
Cell therapy
Good manufacturing practice
Mesenchymal stem cells
Tissue engineering
url http://link.springer.com/article/10.1186/s13287-017-0695-y
work_keys_str_mv AT santiagoroura mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario
AT carolinagalvezmonton mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario
AT clementinemirabel mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario
AT joaquimvives mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario
AT antonibayesgenis mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario
_version_ 1725279448088969216